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S U M M A R Y
Objectives: There is an association between chronic inﬂammation and cancer, including colon cancer.
Cryptosporidium parvum is a protozoan parasite that infects the gastrointestinal epithelial cells causing
several parasitological and pathological changes. It is incriminated in the development of colorectal
cancer in immunosuppressed individuals. Cyclin D1 expression is essential for cell cycle progression and
its overexpression has been reported in colorectal cancer. This work aimed to study the gastrointestinal
changes, including parasitological and pathological changes, induced by C. parvum infection in both
immunocompetent and in chemically immunosuppressed mice, together with immunohistochemical
assessment of cyclin D1 expression in infected tissues. In addition, the effectiveness of nitazoxanide
(NTZ) in the treatment of cryptosporidiosis was evaluated.
Methods: This study included six groups of mice: group I, infected; group II, infected and
immunosuppressed; group III, infected and treated with NTZ; group IV, infected, immunosuppressed,
and treated with NTZ; and groups V and VI representing non-infected controls. Mice were subjected to
stool examination for oocyst counts and were later sacriﬁced for intestinal dissection and routine
histopathological examination of pathological changes; the endogenous developmental stages of the
parasite were counted and immunohistochemical staining was carried out for the determination of
cyclin D1.
Results: Group II showed the highest numbers of oocysts shed and endogenous developmental stages
compared to the other groups. Intestinal dysplastic changes were seen only in groups I and II, where
these changes were in favor of group II compared to group I. High-grade dysplasia was seen in four out of
20 mice in group II and was signiﬁcantly associated with the number of endogenous developmental
stages of C. parvum. NTZ was effective in the treatment of Cryptosporidium infection, with a greater
effect in group III than in group IV.
Conclusions: C. parvum is one of the infectious agents that may induce intestinal dysplasia, including the
high-grade category, which occurs particularly in the presence of immune suppression states and
elevated endogenous parasite loads. Cyclin D1 is a good and useful marker for the detection of intestinal
dysplasia. The effectiveness of NTZ is dependent on the immune status of the infected host.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Cryptosporidium parvum is a globally distributed protozoan
parasite that is found in both vertebrates and invertebrates.1
Infections are transmitted by the fecal–oral route, or through
contaminated food or water, and several major waterborne
outbreaks have occurred.2* Corresponding author. Tel.: +20 48 2282939; fax: +20 48 2233521.
E-mail address: Asmaa_elsaidy@yahoo.com (A.G. Abdou).
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http://dx.doi.org/10.1016/j.ijid.2012.11.023Cryptosporidiosis represents a major health problem as it is a
frequent cause of diarrhea in both immunocompetent and
immunodeﬁcient individuals.3 The risk of developing a severe
disease differs depending on the personal immune status. In
immunocompetent humans, exposure usually results in a self-
limited disease manifested by watery diarrhea with a duration of
about 2 weeks.4 In contrast, in immunocompromised patients the
parasite is of particular clinical signiﬁcance, since it may cause a
severe persistent disease that may be life-threatening.5,6
The immunocompromised population is a diverse group of
individuals whose immune problems can result from an acquired
immune deﬁciency syndrome (AIDS), cancer chemotherapy, orses. Published by Elsevier Ltd. All rights reserved.
A.G. Abdou et al. / International Journal of Infectious Diseases 17 (2013) e593–e600e594organ transplantation.7,8 In addition, pregnant women, preschool
children, and infants are more susceptible to the spread of this
organism.9
C. parvum can be propagated in either chemically (steroids) or
genetically immunosuppressed mice.10 Generally, there is an
association between chronic inﬂammation and cancer; colon
cancer with inﬂammatory bowel disease is a common example of
this association.11
C. parvum causes several pathological changes in gastrointesti-
nal epithelial cells, especially in the immunocompromised host.12
This parasite may result in a higher risk of developing colorectal
malignancies, especially in those with severe immunosuppres-
sion.13
Cyclin Dl protein overexpression has been reported in colon
carcinoma cell lines, in 30-46% of primary colorectal cancers,14,15
and in at least 33% of sporadic colorectal adenomatous polyps in
humans.16 Cyclin Dl expression has been found to be essential for
cell cycle progression in both non-transformed and transformed
cells in which it is expressed, with inhibition of expression
resulting in G1 growth arrest.17
In this work, cryptosporidiosis was studied in both immuno-
competent and in chemically immunosuppressed mice (sup-
pressed with dexamethasone). The intensity of oocyst shedding in
the stool and histopathological changes in the gastrointestinal
tract were examined, focusing on dysplastic changes and the grade
of the dysplasia, together with the immunohistochemical evalua-
tion of the role of cyclin D1 in highlighting these changes. In
addition, examination of the effectiveness of nitazoxanide (NTZ) in
the treatment of cryptosporidiosis was carried out, since no
speciﬁc and effective therapy for this opportunistic infection is yet
available.
2. Materials and methods
2.1. The animal
This study was carried out on laboratory bred Swiss albino
female mice (n = 80) weighing approximately 20 g. They were all
free from any parasitic infection on three consecutive days, as
determined by examining their stools using the formol–ether
concentration method18 and modiﬁed Ziehl–Neelsen technique.19
The experimental animals were categorized into the following
groups: (1) group I (n = 20), divided into two subgroups: Ia, 10 mice
orally infected with Cryptosporidium oocysts and sacriﬁced on day
18 post-infection (PI), and Ib, 10 mice orally infected with
Cryptosporidium oocysts and sacriﬁced on day 30 PI; (2) group
II (n = 20), divided into two subgroups: IIa, 10 mice infected with
Cryptosporidium oocysts, immunosuppressed using oral dexa-
methasone and sacriﬁced on day 18 PI, and IIb, formed of 10 mice
infected with Cryptosporidium oocysts, immunosuppressed using
oral dexamethasone and sacriﬁced on day 30 PI; (3) group III,
formed of 10 infected mice, treated with the tested drug and
sacriﬁced on day 30 PI; (4) group IV, formed of 10 infected mice,
immunosuppressed using oral dexamethasone and then treated
with the tested drug and sacriﬁced on day 30 PI; (5) group V,
formed of 10 non-infected mice, immunosuppressed using oral
dexamethasone (control group); (6) group VI, 10 non-infected
mice (control group).
2.2. Immunosuppression
Immunosuppression was performed by giving the animals
synthetic corticosteroids (dexamethasone) orally at a dose of
0.25 mg/g/day for 14 successive days prior to inoculation with
Cryptosporidium oocysts.20 The mice continued to receive
dexamethasone at the same dose throughout the experiment.2.3. The oocysts
Cryptosporidium oocysts were obtained from naturally infected
calves (from slaughter houses) by collection of scrapings of the
ileal mucous membrane and cecal content.21 The samples were
examined for conﬁrmation of the presence of oocysts by modiﬁed
Ziehl–Neelsen staining method.19 The samples were then pro-
cessed for DNA extraction and PCR ampliﬁcation of C. parvum.22
Genotypic classiﬁcation was achieved using a portion of the 60 kDa
glycoprotein gene (designated pgp60), which identiﬁed the
different strain subtypes.23,24 Subtype IIa A15G2R1 was selected
because it is considered the prevailing subtype in calves and cattle
in many different countries, including European countries and the
USA.25
The infective samples were preserved by mixing with an equal
volume of 2.5% potassium dichromate (K2Cr2O7), in accordance
with Current et al.26 and Campbell and Current.27 The infective
inoculum was prepared in accordance with Reese et al.,28 and the
number of Cryptosporidium oocysts in the concentrated stock
inoculums was determined using a hemocytometer.29
2.4. The infection
All mice in the studied groups except the control groups were
infected orally with the prepared inoculums of Cryptosporidium
oocysts; this occurred on day 15 of dexamethasone in the
immunosuppressed groups.30 The animals were deprived of water
overnight, and were then inoculated intra-esophageally with the
prepared inoculums using a tuberculin syringe connected to a
polythene tube. The amount given to each mouse was adjusted to
contain approximately 105 oocysts.31
2.5. The drugs
All mice in groups III and IV were treated orally with NTZ at a
dose of 500 mg twice daily starting on day 14 PI: for three
consecutive days for immunocompetent mice and for six
consecutive days for immunosuppressed mice. The dose of the
drug was calculated according to the Paget and Barnes table.32 The
drug was administrated to the mice using the same special
syringes that were used for the oocyst inoculation.
2.6. Assessment of infection and the drug effect
2.6.1. Stool examination
Fresh fecal pellets from each mouse in the study groups were
collected separately every 2 days over the 30 days of the
experiment, according to the group to which they were assigned.
Each sample was suspended in 10% formalin and homogenized.
Then, 1 mg was prepared as a fecal smear and stained by the
modiﬁed Ziehl–Neelsen staining method. The stained fecal smear
was examined microscopically and the number of Cryptosporidi-
um oocysts was counted in 10 high-power ﬁelds (HPF); the
number of oocysts per mg for each animal and then for each group
of animals was calculated. The mice in group Ia and group IIa
(infected immunocompetent and infected immunosuppressed)
were sacriﬁced ﬁrst – on day 18 PI – in addition to ﬁve mice from
each non-infected control group (groups V and VI). The remaining
groups continued the experiment to day 30 PI, at which time fresh
fecal pellets were collected, and the mice were then sacriﬁced.
2.6.2. Histopathological examination
The terminal 2 cm of the ileum and the liver were submitted to
routine histopathological processing at the Pathology Department,
Faculty of Medicine, Menoﬁya University, where they were ﬁxed in
10% neutral buffered formalin, dehydrated in ascending grades of
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in parafﬁn. Two 5-mm thick sections were taken from each block.
One section was stained with hematoxylin and eosin for
evaluation, as detailed below.
The severity of infection was assessed by counting the
endogenous stages of the parasite in the epithelium in 10 villous
crypt units; then the mean number per single villous crypt unit for
each animal and for each group of animals was determined.33
The presence of a dysplastic epithelium was investigated, and
when evident was classed as low-grade or high-grade in
accordance with the World Health Organization criteria,34 as
follows: (1) low-grade dysplasia: slightly stratiﬁed spindle or oval
nuclei with apical cytoplasm (roughly half of the total cell height)
and evidence of goblet cell formation; (2) high-grade dysplasia:
stratiﬁed, round nuclei and little cytoplasm (most nuclei reach the
gland lumen) with greater nuclear pleomorphism, little goblet cell
differentiation, reduced or absent cytoplasmic mucin production,
and prominent mitotic ﬁgures.35 This grade also showed architec-
tural changes in the form of irregular branching, budding, or
cribriform conﬁgurations of crypts.36
2.6.3. Immunohistochemical staining for cyclin D1
Other sections of the terminal ileum and liver were cut on
superfrost slides, which were submitted to subsequent steps of
deparafﬁnization, rehydration, blocking of endogenous peroxidase
activity, and antigen retrieval by boiling in 10 mM citrate buffer,
pH 6.0, for 10 min. The tissues were then incubated overnight at
room temperature with primary antibody (at a dilution of 1:100;
rat polyclonal antibody (Sc52893) raised against cyclin D1;
Santa Cruz, USA). The detection kit was the UltraVision Detection
System Anti-Polyvalent HRP/DAB (ready to use) (catalog number
TP-015-HD; Lab Vision, California, USA). A chromogenic reaction
was carried out with DAB substrate and the sections wereFigure 1. Cryptosporidium oocysts in the stool sample of an immunocompromised mo
(highlighted with circles) in the affected intestinal villi (hematoxylin and eosin stainincounterstained with Mayer’s hematoxylin. Mantle cell lymphoma
was used as a positive control. Negative controls obtained by
substitution of primary antibodies with rat-non immune serum
were included in the staining procedure. Nuclear staining in any
number of cells was required to assign cyclin D1 positivity.
2.7. Statistical analysis
Data were collected, tabulated, and statistically analyzed using
SPSS program version 11. Fisher’s exact test was used to compare
qualitative variables, while the Student’s t-test was used in
comparisons between quantitative variables. A p-value equal to or
less than 0.05 was considered signiﬁcant.
3. Results
3.1. Oocyst shedding
Maximum shedding of C. parvum oocysts (Figure 1A) in
immunocompetent mice (groups Ia and Ib) was observed on days
13 and 15 PI, with a mean of 3.2  0.83, while in immunosuppressed
mice (groups IIa and IIb), the mean number of oocysts shed in the
stools on the same days was 4.8  0.83; this difference was
statistically signiﬁcant (p < 0.0001). After NTZ treatment, infected
immunocompetent mice (group III) showed a marked decrease in
oocyst shedding, until it nearly ceased on day 21 PI in eight out of the
10 of mice in this group, while two of 10 continued to shed oocysts
until day 30 PI. However, the mice in group Ib, which did not receive
treatment, also showed a progressive decline in oocyst shedding, with
almost complete cessation of oocyst production at the end of the
experiment (day 30 PI). There was a difference between treated and
untreated immunocompetent mice (groups III and Ib, respectively)use (1000) (A). The endogenous developmental stage of Cryptosporidium parvum
g 600) (B and C).
Table 1
Comparisons between the different study groups with regard to the number of oocysts of Cryptosporidium parvum shed
Group Shed oocysts/mg,
mean  SD
Time of stool
examination
P1a P2a P3a P4a
Group I 3.2  0.83 15 days PI T = 6.096 T = 0.94 T = 8.037 T = 3.91
Group Ib 1  1 30 days PI p < 0.0001 p = 0.35 p < 0.0001 p = 0.001
Group II 4.8  0.83 15 days PI
Group IIb 5.4  1.14 30 days PI
Group III 0.6  0.89 30 days PI
Group IV 2  0.70 30 days PI
PI, post infection; T, Student’s t-test.
a P1 tests the difference between groups I and II; P2 tests the difference between groups Ib and III; P3 tests the difference between groups IIb and IV; P4 tests the difference
between groups III and IV.
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(p > 0.05) (Table 1).
In infected immunosuppressed mice (group IV), NTZ caused
irregular shedding of oocysts until it dropped to a mean of 2  0.70
on the last day of the experiment. This was signiﬁcantly higher than
that of treated immunocompetent mice (group III, 0.6  0.89;
p = 0.001). Group IIa and group IIb included the infected immuno-
suppressed mice that did not receive treatment and these showed
high levels of oocyst shedding throughout the study period with a
mean of 4.8  0.83 at day 15 PI in group IIa and 5.4  1.14 in group IIb
on the last day. Four mice in this group died before the end of the
experiment. The difference between treated and untreated immu-
nosuppressed mice (groups IV and IIb, respectively) was statistically
signiﬁcant (p < 0.0001). Groups V and VI representing control normal
mice and control immunosuppressed mice showed no oocysts in their
stools (Table 1).
3.2. Detection of endogenous developmental stages of
cryptosporidiosis
The ileum was the site with the heaviest burden of intestinal
cryptosporidiosis (Figure 1, B and C). In group Ia, the mean number
of endogenous developmental stages of the parasite at the end of
day 18 PI was 8.078  2.5, while it was 12.91  2.3 in group IIa; this
difference was statistically signiﬁcant (p = 0.0003). However, on day
30 PI it was observed that there was a signiﬁcant decrease in the mean
number of endogenous developmental stages of Cryptosporidium in
group Ib (1.03  1.04), with a signiﬁcant difference compared to
group Ia (p < 0.0001). In group IIb, it continued to increase to reach
15.63  4.7 on day 30 PI, with a signiﬁcant difference between group
Ib and group IIb (p < 0.0001) (Table 2).
After receiving NTZ, it was found that the mean number of the
endogenous developmental stages of the parasite in group III
dropped markedly to 0.956  0.49 on day 30 PI, while it was
3.29  0.9 in group IV; this difference was highly signiﬁcant
(p < 0.0001). Also, there was a signiﬁcant difference (p < 0.0001) in
the mean number of endogenous developmental stages of Crypto-
sporidium on day 30 PI between group IIb (15.63  4.7) and group IV
(3.29  0.9) (Table 2).Table 2
Comparisons between the different study groups with regard to the number of endoge
Group Developmental stages/villous unit,
mean  SD
Day of sacriﬁce P1
Group Ia 8.078  2.5 18 days PI T =
Group Ib 1.03  1.04 30 days PI p <
Group IIa 12.91  2.3 18 days PI
Group IIb 15.63  4.7 30 days PI
Group III 0.956  0.49 30 days PI
Group IV 3.29  0.9 30 days PI
PI, post infection; T, Student’s t-test.
a P1 tests the difference between groups Ia and Ib; P2 tests the difference between 
difference between groups IIb and IV; P5 tests the difference between groups III and I3.3. Histopathological changes
Several degrees of inﬂammatory changes were seen in the
groups infected with the parasites, both immunocompetent and
immunosuppressed. As regards dysplasia, most dysplastic changes
were seen in group II (a and b), featuring low-grade dysplasia in
most of the cases (16/20, 80%) (Figure 2A), while high-grade
dysplasia was seen in four cases (40%) in group IIb (Figure 2, B and
C) and one of these cases also showed large cell dysplasia of the
liver (Figure 3, A and B). Low-grade dysplastic changes were also
seen in four mice (40%) belonging to group Ib, with a signiﬁcant
difference compared to group II (p < 0.0001) (Table 3). No evidence
of dysplasia was seen in the other groups and no frank carcinoma
developed throughout the experiment (30 days). In group II, the
development of high-grade dysplastic changes was signiﬁcantly
(p < 0.05) associated with the number of endogenous develop-
mental stages of the parasite, since high-grade dysplasia was
associated with a higher mean number (18.85  2.6) compared to
low-grade dysplasia (13.12  3.165) (Table 4).
3.4. Immunohistochemical staining of cyclin D1
The dysplastic nuclei of both low- and high-grade were strongly
stained for cyclin D1 (Figure 4, A and B).
4. Discussion
Cryptosporidium species are common causes of gastroenteritis
associated with severe life-threatening illnesses among immuno-
compromised individuals.37 Host cell immunity against crypto-
sporidiosis is mediated by both Th1 and Th2 responses.38,39 Also, it
has been found that there is an interferon gamma (IFN-g) mucosal
response with increased levels of interleukin 15 during crypto-
sporidiosis. IFN-g has been reported to induce enterocyte
resistance against C. parvum.40,41
In the current work, dexamethasone, a synthetic glucocorticoid,
was used to induce chemical immunosuppression in the mice.
Glucocorticoids are known to have an effect on the priming of thenous developmental stages of Cryptosporidium parvum
a P2a P3a P4a P5a
 8.32 T = 4.49 T = 9.59 T = 8.15 T = 7.19
 0.0001 p = 0.0003 p < 0.0001 p < 0.0001 p < 0.0001
groups Ia and IIa; P3 tests the difference between groups Ib and IIb; P4 tests the
V.
Figure 2. The affected intestinal epithelium showing low-grade dysplasia in the form of enlarged hyperchromatic nuclei that still showed apical cytoplasm (hematoxylin and
eosin staining 400) (A). Intestinal epithelium showing high-grade dysplasia manifested by great pleomorphism, absence of mucin, and frequent mitoses (arrows)
(hematoxylin and eosin staining 600) (B and C).
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expression.43
This study was carried out over a period of 30 days to evaluate
the course of infection. Matsui et al.44 reported that the interval
which covers the natural shedding period of Cryptosporidium
infection in mice is about 24 days; Lacroix et al.12 found that the
duration of oocyst shedding was about 3–4 weeks.The intensity of
oocyst shedding was signiﬁcantly higher in dexamethasone
immunosuppressed mice than in immunocompetent ones
throughout the duration of the experiment. Similar results have
been reported by Kapel et al.,45 Chai et al.,46 and Certad et al.13 The
maximum shedding of oocysts in immunocompetent mice
(groups Ia and Ib) was observed on days 13 and 15 PI, in
agreement with Miller et al.9 and Certad et al.,13 and for the
majority no oocysts were detected in the stool at the end of the
experiment (group Ib). On the other hand, dexamethasone
immunosuppressed mice (group IIa and IIb) showed high levels
of oocyst shedding throughout and at the end of the experiment
(group IIb). These results are in agreement with those of several
studies.13,47–49
Regarding the histopathological ﬁndings, the terminal part of
the ileum was found to be the site with the heaviest burden of
infection in both immunocompetent and immunosuppressed
mice, in agreement with the ﬁndings of others.8,41,45,50 It has
been suggested that conditions in the ileum are favorable,
including biochemical conditions and the presence of speciﬁc
receptors, and contribute to the development of the parasite.51
Also, Certad et al.13 found that parasitic localization and
histopathological changes were mainly localized to the ileocecal
region. The dysplastic changes observed in the current study were
mainly of low-grade category, seen in 40% of group Ib and 80% of
groups IIa and IIb, with only four cases (40%) belonging to group IIb
showing high-grade dysplasia. The development of adenoma andintraepithelial neoplasia (synonymous with dysplasia) has also
been reported by others using dexamethasone in treated adult
severe combined immunodeﬁciency (SCID) mice.13 In the present
study, no frank carcinoma was detected, while Certad et al.52
observed the development of intramucosal carcinoma with a
suspicion of submucosal invasion in four mice in their experiment.
The absence of frank carcinoma in our work could be related to the
degree of immunosuppression used, which relied on dexametha-
sone; other studies used the SCID mouse model in addition to
dexamethasone.13,51 As the degree of immunosuppression in-
creased, the risk of neoplastic transformation increased. In
addition, they used different strains of Cryptosporidium, such as
C. parvum IOWA and C. parvum TUM1, as in Certad et al.52
According to the latter study, C. parvum TUM1 strain seemed to
induce a more severe illness than C. parvum IOWA, with an earlier
onset of neoplastic lesions that rapidly progressed to invasive
cancer on day 20 PI.52
Although the present results showed mostly low-grade
dysplasia induced by C. parvum, these changes still represent a
potential precursor to digestive carcinoma. The prevalence of C.
parvum in patients with colorectal cancer reached 18%, primarily in
those with tumors located on the left side (in the sigmoid and
descending colon). Furthermore, an epidemiological study per-
formed in Poland reported a high frequency of cryptosporidiosis in
patients with colorectal cancer.53
In the current study, a signiﬁcant correlation was found
between the development of high-grade dysplasia and the number
of endogenous developmental stages of the parasite (p < 0.05).
This reﬂects the impact of parasite load on neoplastic transforma-
tion. According to Certad et al.,52 histopathological evidence of
dysplasia in any organ was always associated with the presence of
the parasite, and an elevated parasite load was correlated with the
severity of ileocecal pathological changes.
Figure 3. Large cell dysplasia of the liver in one of the infected mice manifested by
irregular and abnormal hyperchromatic nuclei (hematoxylin and eosin staining,
200 (A) and 400 (B)).
Table 4
The relationship between grade of dysplasia and the number of endogenous
developmental stages of Cryptosporidium parvum in group II
Low-grade
dysplasia
(n = 16)
High-grade
dysplasia
(n = 4)
Test
Developmental stage,
mean  SD
13.12  3.165 18.85  2.6 T = 2.337
p = 0.04
T, Student’s t-test.
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reported with evidence of dysplastic changes in the bile duct, for
example.52 In the current study, there was one case demonstrating
large cell dysplasia in the liver, which was concomitantly
associated with high-grade ileal dysplasia; we believe that such
an observation has not been reported previously.
Since reactive atypical changes secondary to inﬂammation and
infection could morphologically affect the epithelium of the
gastrointestinal tract and simulate true dysplastic changes,
determining the true dysplastic process using speciﬁc markers is
required. In the present study, the use of one cell cycle regulator –
cyclin D1 – helped to identify true dysplasia. As a nuclear marker,
its evaluation is reproducible, and we found it to stain the nuclei in
dysplastic areas of both low- and high-grade categories. However,
cyclin D1 did not stain normal areas; these ﬁndings agree with
others.54,55 In the latter study, cyclin D1 was detected in theTable 3
Dysplastic changes in the different study groupsa
Groups Group Ia Group Ib Group IIa Group IIb Group III Group IV
Dysplasia
Positive 0 4 6 10 0 0
Negative 10 6 4 0 20 20
a Ia and Ib versus IIa and IIb, Fisher’s exact test p = 0.0004.intestinal adenomas of familial adenomatous polyposis syndrome
and was associated with proliferative activity and the severity of
dysplasia in these premalignant lesions. The authors suggested
that abnormal upregulation of cyclin D1 may be an early event in
intestinal carcinogenesis.55
The endogenous developmental stages of the parasite were
detected in sections obtained from immunocompetent mice at a
high level on day 18 PI (group Ia). However on the last day of the
experiment (day 30 PI), few were detected in histological sections
(group Ib, Table 2). These ﬁndings are in agreement with Lacroix
et al.12 and Takeuchi et al.,56 who found that the immune system
and defense mechanisms are able to ﬁght the infection and reject
the parasite rapidly in the immunocompetent host. On the other
hand, the endogenous developmental stages of the parasite were
detected in histological sections obtained from dexamethasone-
immunosuppressed mice in both group IIa and group IIb with a
statistically signiﬁcant difference in comparison to the other
groups of immunocompetent mice (Table 2). These results could be
attributed to the suppression of the immune system by dexa-
methasone, making clearance of Cryptosporidium organisms very
difﬁcult, which then increased the severity and duration of
infection in immunosuppressed mice. The ﬁndings of several
studies suggest that the mucosal immune defenses play a major
role in preventing Cryptosporidium infection and that the common
factor in immunosuppressed mice is the suppression of lympho-
cytes that leads to chronic infection.41,57,58
Many compounds have been tested for their potential anti-
cryptosporidial activity, but there is no efﬁcient therapy to prevent
or treat cryptosporidiosis, particularly in the immunocompro-
mised host.5,59 The parasite’s unique location in the host cell may
affect the drug concentration, and the existence of transport
proteins or efﬂux pumps that transport drugs out of the parasite or
into the host cells provides the Cryptosporidium organisms with
resistance to drug therapy. This explains why many therapies are
not effective against the parasite.
NTZ and other nitrothiazole salicylamide compounds have
broad antiparasitic activities.60 In the present study, NTZ was
tested as a treatment for cryptosporidiosis in both the experimen-
tally infected immunocompetent and dexamethasone-immuno-
suppressed groups (group III and group IV, respectively). Our study
demonstrated the effectiveness of NTZ in both groups with
signiﬁcant differences regarding levels of oocyst excretion in the
stool and the number of endogenous developmental stages of the
parasite in both groups, being lower in group III (immunocompe-
tent mice) than in group IV (p < 0.05) (Tables 1 and 2). These
results agree with those of Bailey and Erramouspe61 and Fox and
Saravolatz,62 who found that the responses to the drug were lower
in immunocompromised individuals. Also, Gargala63 found that
NTZ signiﬁcantly shortened the duration of diarrhea and decreased
mortality in adults and in malnourished children. However, the
latter study showed that NTZ is not effective without an
appropriate immune response, in which a competent immune
system is needed to reject the parasite. Rossignol reported the
variability of the effectiveness of NTZ, which depended on the
degree of immunosuppression and CD4 counts.3
Figure 4. Nuclear expression of cyclin D1 in the dysplastic intestinal epithelium
infected by Cryptosporidium parvum (immunohistochemical staining, 100 (A) and
200 (B)).
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number of oocysts per milligram after the initiation of therapy in
group III, the results showed no signiﬁcant difference (p < 0.05)
when compared to group Ib, and no oocysts were detected in the
stools of either group by the end of the experiment. It is clear that
the competent immune system rejected the parasite and that it
caused a self-limited disease in the untreated group, while infected
untreated immunosuppressed mice (group IIb) still showed a high
level of oocyst excretion until the last day of the experiment
(Table 1). This may be due to a failure of the immune system to
eradicate the parasite. Similar ﬁndings have been recorded in
several studies including in vitro and in vivo studies using several
animal models and in clinical trials, which have demonstrated the
effectiveness of NTZ in treating diarrhea and enteritis caused by
Cryptosporidium species in immunocompetent patients.61,64 On the
other hand, Amadi et al.65 found no signiﬁcant effect of NTZ on the
eradication of cryptosporidial infections in Zambian children with
HIV-related immunosuppression.
In conclusion, Cryptosporidium parvum is one of the infectious
agents that may induce intestinal dysplasia, even of high-grade
category, which is highly affected by immune suppression states
and elevated endogenous parasite loads. Cyclin D1 is a good and
useful marker for the detection of intestinal dysplasia. The
effectiveness of NTZ is dependent on the immune status of the
infected host.
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